Form 4: MAIA Biotechnology Director Stan Smith Receives Stock Options
Insider Transaction Report
MAIA Biotechnology Director Stan Smith was granted 29,216 stock options at an exercise price of $1.53, vesting immediately.
Summary
- Stan Smith, a Director of MAIA Biotechnology, Inc. (MAIA), was granted 29,216 derivative securities in the form of stock options.
- The options have an exercise price of $1.53 per share.
- The grant date for these options was December 31, 2025.
- The options vest 100% on the date of the grant and are exercisable beginning as of December 31, 2025.
- The expiration date for these stock options is December 31, 2035.
- The options were granted pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan.
- Mr. Smith beneficially owns these securities indirectly through The Stan V. Smith Trust Dated 1993.
Sentiment
Score: 6
Explanation: The grant of stock options to a director is a routine event that aligns the director's interests with shareholders, generally viewed as a neutral to slightly positive corporate governance practice.
Positives
- The grant of stock options aligns the director's financial interests with the long-term performance and shareholder value of MAIA Biotechnology, Inc.
Future Outlook
NA
Industry Context
This filing reflects a routine insider transaction where a director receives equity compensation, a common practice in the biotechnology industry to align management and director interests with shareholder value.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Equity Compensation | Grant of 29,216 stock options to Director Stan Smith under the MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan. | 12/31/2025 | Aligns director's long-term interests with shareholder value and incentivizes performance. |
Related Party Transactions
- The securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993, indicating an indirect beneficial ownership arrangement.
Stakeholder Impact
- Shareholders: The grant of options aligns the director's financial interests with the company's performance, potentially encouraging decisions that enhance shareholder value.
Next Steps
- Mr. Smith may choose to exercise these options at any time before their expiration date of December 31, 2035.
Key Dates
| Date | Description |
|---|---|
| 12/31/2025 | Date of earliest transaction, grant date, vesting date, and exercisable date for stock options. |
| 01/05/2026 | Date the Form 4 was signed and filed. |
| 12/31/2035 | Expiration date of the stock options. |
Keywords
MAIA Biotechnology, MAIA, Stan Smith, Stock Options, Insider Transaction, Form 4, Equity Incentive Plan, Director
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.